Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1898416rdf:typepubmed:Citationlld:pubmed
pubmed-article:1898416lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C0225828lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C1522565lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C0021547lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:1898416lifeskim:mentionsumls-concept:C1522492lld:lifeskim
pubmed-article:1898416pubmed:issue2lld:pubmed
pubmed-article:1898416pubmed:dateCreated1991-10-22lld:pubmed
pubmed-article:1898416pubmed:abstractTextIn adult cultured rat ventricular cardiac myocytes, both the alpha-adrenergic agonist phenylephrine and the selective kappa opioid receptor ligand U-50, 488H affected phosphoinositide turnover. Phenylephrine, over a time course of 10 min, caused a transient increase in Ins(1,4,5)P3 which peaked at 1 min and had returned to control at 2 min. In addition, phenylephrine produced a progressive and sustained increase in the formation of Ins (1,3,4,5)P4 which achieved a plateau after 5 min of exposure to the agonist. U-50,488H induced an increase in Ins(1,4,5)P3 which peaked at 1 min at a level significantly higher than that due to phenylephrine and was still elevated after 10 min exposure to the kappa opioid receptor agonist. In addition, U-50,488H caused a sustained increase in Ins(1,3,4,5)P4 which was comparable to that due to phenylephrine. The stimulatory effects produced by phenylephrine and U-50,488H were receptor-mediated events, since they were fully antagonized by their respective antagonists, phentolamine or Mr-1452.lld:pubmed
pubmed-article:1898416pubmed:languageenglld:pubmed
pubmed-article:1898416pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:citationSubsetIMlld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1898416pubmed:statusMEDLINElld:pubmed
pubmed-article:1898416pubmed:monthSeplld:pubmed
pubmed-article:1898416pubmed:issn0006-291Xlld:pubmed
pubmed-article:1898416pubmed:authorpubmed-author:LakattaE GEGlld:pubmed
pubmed-article:1898416pubmed:authorpubmed-author:VenturaCClld:pubmed
pubmed-article:1898416pubmed:authorpubmed-author:GuarnieriCClld:pubmed
pubmed-article:1898416pubmed:authorpubmed-author:CapogrossiM...lld:pubmed
pubmed-article:1898416pubmed:authorpubmed-author:StefanelliCClld:pubmed
pubmed-article:1898416pubmed:authorpubmed-author:CirielloEElld:pubmed
pubmed-article:1898416pubmed:issnTypePrintlld:pubmed
pubmed-article:1898416pubmed:day16lld:pubmed
pubmed-article:1898416pubmed:volume179lld:pubmed
pubmed-article:1898416pubmed:ownerNLMlld:pubmed
pubmed-article:1898416pubmed:authorsCompleteYlld:pubmed
pubmed-article:1898416pubmed:pagination972-8lld:pubmed
pubmed-article:1898416pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:meshHeadingpubmed-meshheading:1898416-...lld:pubmed
pubmed-article:1898416pubmed:year1991lld:pubmed
pubmed-article:1898416pubmed:articleTitleComparison between alpha-adrenergic- and K-opioidergic-mediated inositol (1,4,5)P3/inositol (1,3,4,5) P4 formation in adult cultured rat ventricular cardiomyocytes.lld:pubmed
pubmed-article:1898416pubmed:affiliationInstitute of Biochemistry, University of Sassari, Italy.lld:pubmed
pubmed-article:1898416pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1898416pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1898416lld:pubmed